Unlocking the Immune System to Attack Cancer    

Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. Neon Therapeutics’ lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in multiple clinical trials.

Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

January 5, 2017
Neon Therapeutics Secures $70 Million in Series B Financing

December 28, 2016
Neon Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference

November 17, 2016
Neon Therapeutics Announces First Patient Enrolled in Inaugural Clinical Trial for Personalized Cancer Vaccine NEO-PV-01

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Robert Tepper, M.D.

Robert Kamen, Ph.D.

Stephen Sherwin, M.D.
Venture Partner